Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Dezember 2022 17:30 ET | Quelle: Genmab A/S

Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Media Release COPENHAGEN, Denmark; December 11, 2022 Epcoritamab featured in multiple data disclosures, including four oral presentationsResults presented from the phase 1b/2 EPCORE™ NHL-2 trial...
23. November 2022 14:56 ET | Quelle: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; November 23, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
21. November 2022 14:44 ET | Quelle: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; November 21, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
21. November 2022 14:39 ET | Quelle: Genmab A/S

Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; November 21, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 11,608 restricted stock units to members of the Board of...
21. November 2022 08:00 ET | Quelle: Genmab A/S

Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Media Release COPENHAGEN, Denmark; November 21, 2022 Epcoritamab BLA accepted for FDA Priority review; FDA action date is May 21, 2023Epcoritamab could become the first subcutaneous bispecific...
15. November 2022 13:54 ET | Quelle: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; November 15, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 57,442 shares as a consequence of the exercise of employee warrants. The...
14. November 2022 12:30 ET | Quelle: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; November 14, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
10. November 2022 08:27 ET | Quelle: Genmab A/S

Genmab to Present at Jefferies London Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; November 10, 2022 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony Pagano...
09. November 2022 11:01 ET | Quelle: Genmab A/S

Genmab Announces Financial Results for the First Nine Months of 2022

November 9, 2022 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2022 Highlights Genmab revenue increased 60% compared to the first nine months of 2021, to DKK...
03. November 2022 12:45 ET | Quelle: Genmab A/S

Genmab Improves Its 2022 Financial Guidance

Company Announcement Genmab improves its 2022 financial guidance COPENHAGEN, Denmark; November 3, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2022 financial guidance...

Vorherige Seite

Nächste Seite